Get the Stockscreener App
2.97
5.69%
0.16
Onconetix Inc stock is traded at $2.97, with a volume of 91,290.
It is up +5.69% in the last 24 hours and down -21.22% over the past month.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
See More
Previous Close:
$2.81
Open:
$2.82
24h Volume:
91,290
Relative Volume:
0.14
Market Cap:
$4.59M
Revenue:
-
Net Income/Loss:
$-53.12M
P/E Ratio:
-0.0273
EPS:
-108.8
Net Cash Flow:
$-15.86M
1W Performance:
+1.37%
1M Performance:
-21.22%
6M Performance:
-91.29%
1Y Performance:
-99.45%
1-Day Range:
$2.81
$3.0391
1-Week Range:
$2.62
$3.07
52-Week Range:
$2.61
$552.50
Onconetix Inc Stock (ONCO) Company Profile
Name
Onconetix Inc
Sector
Industry
Phone
513-620-4101
Address
201 E. FIFTH STREET, CINCINNATI
Compare ONCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
2.97 | 1.54M | 0 | -53.12M | -15.86M | -108.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Onconetix Inc Stock (ONCO) Latest News
Custom watchlist performance reports with Onconetix Inc.Earnings Trend Report & Scalable Portfolio Growth Methods - Newser
How to manage a losing position in Onconetix Inc.Index Update & Weekly High Momentum Picks - Newser
Can Onconetix Inc. rally from current levelsMarket Sentiment Review & Weekly Hot Stock Watchlists - Newser
Onconetix faces Nasdaq delisting over share price rule - MSN
Smart tools for monitoring Onconetix Inc.’s price actionWeekly Market Summary & Long-Term Growth Stock Strategies - Newser
Chart based exit strategy for Onconetix Inc.Jobs Report & Weekly Consistent Profit Watchlists - Newser
Price action breakdown for Onconetix Inc.Market Movers & Low Drawdown Momentum Ideas - Newser
Applying Wyckoff theory to Onconetix Inc. stockJuly 2025 News Drivers & AI Powered Market Entry Ideas - Newser
Exit strategy if you’re trapped in Onconetix Inc.2025 Volume Leaders & Community Verified Watchlist Alerts - Newser
Onconetix Inc. stock trend forecastMarket Volume Report & Free Weekly Chart Analysis and Trade Guides - Newser
Why Onconetix Inc. stock attracts strong analyst attentionEarnings Recap Summary & Safe Investment Capital Preservation Plans - Newser
Has Onconetix Inc. formed a bullish divergencePortfolio Gains Summary & Real-Time Market Trend Scan - Newser
Live market analysis of Onconetix Inc.Quarterly Earnings Report & Verified Trade Idea Suggestions - Newser
Visualizing Onconetix Inc. stock with heatmapsTrade Risk Report & AI Based Buy and Sell Signals - Newser
Using data models to predict Onconetix Inc. stock movementWeekly Trade Summary & Growth Oriented Trading Recommendations - Newser
Short interest data insights for Onconetix Inc.Weekly Trading Summary & Verified Momentum Watchlists - Newser
Visual trend scoring systems applied to HYFM2025 EndofYear Setup & Growth Focused Stock Pick Reports - Newser
Quantitative breakdown of Onconetix Inc. recent moveM&A Rumor & Safe Swing Trade Setups - Newser
Real time breakdown of Onconetix Inc. stock performanceWeekly Trend Report & Daily Profit Focused Stock Screening - Newser
Live Scanner Shows Breakout on Onconetix Inc.July 2025 Institutional & Low Drawdown Trading Strategies - classian.co.kr
Is This a Bottoming Phase for Onconetix Inc.Market Trend Report & Verified Chart Pattern Signals - classian.co.kr
Onconetix 2025 Q2 Earnings Cautious Optimism Amid 83.4% Net Loss Reduction - AInvest
RSI and MACD Indicate Shift in Onconetix Inc. SentimentJuly 2025 Opening Moves & Consistent Return Strategy Ideas - thegnnews.com
Onconetix, Inc. SEC 10-Q Report - TradingView
Onconetix Director Resignation Amid Financial Adjustments - MSN
Comparing Onconetix Inc. in custom built stock radarsEarnings Miss & Smart Money Movement Tracker - Newser
Top Risks to Consider Before Buying Onconetix Inc. StockCapital Growth Plan for New Investors - Newser
How Onconetix Inc. stock performs during market volatilityFree Step-by-Step Trade Signal Implementation - Newser
Can machine learning forecast Onconetix Inc. recoveryEntry Confirmation Using Short-Term Forecasting - Newser
Onconetix Inc Stock (ONCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):